$0
Adaptimmune Completes Afami-cel Rolling BLA Submission in Advanced SS
On Wednesday, December 6, Adaptimmune announced (press release) the completion of the afami-cel (MAGE-A4 SPEAR T-cell) rolling BLA submission for the treatment of advanced synovial sarcoma (SS). Of note, the submission is supported by results from Cohort 1 of the pivotal Ph2 SPEARHEAD-1 trial. Below, Celltelligence provides insights on afami-cel’s results in r/r SS, while discussing the potential path of lete-cel (NY-ESO-1 TCR-T) in the same indication.